RU2005132163A - 2- (BUTYL-1-SULFONILAMINO) -N- [1 (R) - (6-METHOXYpyridin-3-IL) -PROPYL] BENZAMIDE, ITS APPLICATION AS A MEDICINAL PRODUCT, AND ALSO CONTAINING HIS PHARES - Google Patents

2- (BUTYL-1-SULFONILAMINO) -N- [1 (R) - (6-METHOXYpyridin-3-IL) -PROPYL] BENZAMIDE, ITS APPLICATION AS A MEDICINAL PRODUCT, AND ALSO CONTAINING HIS PHARES Download PDF

Info

Publication number
RU2005132163A
RU2005132163A RU2005132163/04A RU2005132163A RU2005132163A RU 2005132163 A RU2005132163 A RU 2005132163A RU 2005132163/04 A RU2005132163/04 A RU 2005132163/04A RU 2005132163 A RU2005132163 A RU 2005132163A RU 2005132163 A RU2005132163 A RU 2005132163A
Authority
RU
Russia
Prior art keywords
methoxypyridin
benzamide
propyl
butyl
sulfonylamino
Prior art date
Application number
RU2005132163/04A
Other languages
Russian (ru)
Other versions
RU2333202C2 (en
Inventor
Йоахим БРЕНДЕЛЬ (DE)
Йоахим Брендель
Хайнц ГЕГЕЛЯЙН (DE)
Хайнц Гегеляйн
Клаус ВИРТ (DE)
Клаус ВИРТ
Герт Ульрих КЮРЦЕЛЬ (DE)
Герт Ульрих КЮРЦЕЛЬ
Original Assignee
Санофи-Авентис Дойчланд Гмбх (De)
Санофи-Авентис Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис Дойчланд Гмбх (De), Санофи-Авентис Дойчланд Гмбх filed Critical Санофи-Авентис Дойчланд Гмбх (De)
Publication of RU2005132163A publication Critical patent/RU2005132163A/en
Application granted granted Critical
Publication of RU2333202C2 publication Critical patent/RU2333202C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (8)

1. 2-(Бутил-1-сульфониламино)-N-[1(R)-(6-метоксипиридин-3-ил)пропил]бензамид формулы (I) и его физиологически приемлемые соли1.2- (Butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3-yl) propyl] benzamide of the formula (I) and its physiologically acceptable salts
Figure 00000001
Figure 00000001
 2. 2-(Бутил-1-сульфониламино)-N-[1(R)-(6-метоксипиридин-3-ил)пропил]бензамид по п.1.2. 2- (Butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3-yl) propyl] benzamide according to claim 1. 3. 2-(Бутил-1-сульфониламино)-N-[1(R)-(6-метоксипиридин-3-ил)пропил]бензамид и/или его физиологически приемлемые соли по п.1 и/или 2 для применения в качестве лекарственного средства.3. 2- (Butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3-yl) propyl] benzamide and / or its physiologically acceptable salts according to claim 1 and / or 2 for use in as a medicine. 4. Применение 2-(бутил-1-сульфониламино)-N-[1(R)-(6-метоксипиридин-3-ил)пропил]бензамида и/или его физиологически приемлемых солей по п.1 и/или 2 для получения лекарственного средства для лечения или профилактики нарушений ритма сердца, наджелудочковых аритмий, мерцательной аритмии и/или предсердного трепетания.4. The use of 2- (butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3-yl) propyl] benzamide and / or its physiologically acceptable salts according to claim 1 and / or 2 to obtain drugs for the treatment or prevention of cardiac arrhythmias, supraventricular arrhythmias, atrial fibrillation and / or atrial flutter. 5. Фармацевтическая композиция для применения для человека или животного, содержащая эффективное количество 2-(бутил-1-сульфониламино)-N-[1(R)-(6-метоксипиридин-3-ил)-пропил]бензамида формулы (I) и/или его физиологически приемлемых солей по п.1 и/или 2 вместе с фармацевтически приемлемыми носителями и добавками.5. A pharmaceutical composition for use in humans or animals, containing an effective amount of 2- (butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3-yl) propyl] benzamide of the formula (I) and / or its physiologically acceptable salts according to claim 1 and / or 2 together with pharmaceutically acceptable carriers and additives. 6. Фармацевтическая композиция по п.5, отличающаяся тем, что дополнительно содержит одно или несколько других фармакологических активных веществ.6. The pharmaceutical composition according to claim 5, characterized in that it further comprises one or more other pharmacological active substances. 7. 1(R)-(6-метоксипиридин-3-ил)пропиламин.7.1 (R) - (6-methoxypyridin-3-yl) propylamine. 8. Применение 1(R)-(6-метоксипиридин-3-ил)пропиламина в качестве промежуточного продукта для получения 2-(бутил-1-сульфониламино)-N-[1(R)-(6-метоксипиридин-3-ил)пропил]бензамида и/или его физиологически приемлемых солей.8. The use of 1 (R) - (6-methoxypyridin-3-yl) propylamine as an intermediate to obtain 2- (butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3-yl ) propyl] benzamide and / or its physiologically acceptable salts.
RU2005132163/04A 2003-03-18 2004-03-05 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxypyridine-3-yl)-propyl]benzamide, application thereof as medication, and pharmaceutical compositions including same RU2333202C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10312073A DE10312073A1 (en) 2003-03-18 2003-03-18 2- (Butyl-1-sulfonylamino) -N- [1 (R) - (6-methoxypyridin-3yl) -propyl] -benzamide, its use as a medicament and pharmaceutical compositions containing the same
DE10312073.4 2003-03-18

Publications (2)

Publication Number Publication Date
RU2005132163A true RU2005132163A (en) 2006-04-10
RU2333202C2 RU2333202C2 (en) 2008-09-10

Family

ID=32920928

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005132163/04A RU2333202C2 (en) 2003-03-18 2004-03-05 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxypyridine-3-yl)-propyl]benzamide, application thereof as medication, and pharmaceutical compositions including same

Country Status (22)

Country Link
EP (1) EP1606237A1 (en)
JP (1) JP2006520343A (en)
KR (1) KR20050110681A (en)
CN (1) CN100361943C (en)
AR (1) AR043622A1 (en)
AU (1) AU2004222137A1 (en)
BR (1) BRPI0408441A (en)
CA (1) CA2519022A1 (en)
DE (1) DE10312073A1 (en)
HK (1) HK1086819A1 (en)
HR (1) HRP20050815A2 (en)
MA (1) MA27749A1 (en)
MX (1) MXPA05009763A (en)
MY (1) MY176510A (en)
NO (1) NO20054472L (en)
NZ (1) NZ542476A (en)
PE (1) PE20050307A1 (en)
RS (1) RS20050690A (en)
RU (1) RU2333202C2 (en)
TW (1) TW200500342A (en)
WO (1) WO2004083157A1 (en)
ZA (1) ZA200506328B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004009931A1 (en) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Use of specific 2-substituted benzamides for treating and preventing cardiac insufficiency, especially where caused by diastolic dysfunction, act by inhibition of the Kv1.5 potassium channel
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028845A1 (en) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh New substituted pyrrolidin-2-ones, piperidin-2-ones and isothiazolidine-1,1-dioxides useful for treating e.g. dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, breast cancer and heart failure
US8278317B2 (en) * 2005-07-22 2012-10-02 Merck Sharp & Dohme Corp. Potassium channel inhibitors
CA2761639C (en) * 2009-05-29 2016-06-07 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121003A1 (en) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilic acid amides, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
CN1756728A (en) 2006-04-05
HK1086819A1 (en) 2006-09-29
BRPI0408441A (en) 2006-04-04
PE20050307A1 (en) 2005-06-08
WO2004083157A1 (en) 2004-09-30
MY176510A (en) 2020-08-12
ZA200506328B (en) 2006-04-26
CA2519022A1 (en) 2004-09-30
MXPA05009763A (en) 2006-01-27
RS20050690A (en) 2008-04-04
NO20054472L (en) 2005-09-27
JP2006520343A (en) 2006-09-07
AR043622A1 (en) 2005-08-03
KR20050110681A (en) 2005-11-23
AU2004222137A1 (en) 2004-09-30
CN100361943C (en) 2008-01-16
EP1606237A1 (en) 2005-12-21
DE10312073A1 (en) 2004-09-30
HRP20050815A2 (en) 2006-09-30
RU2333202C2 (en) 2008-09-10
NZ542476A (en) 2008-05-30
MA27749A1 (en) 2006-02-01
TW200500342A (en) 2005-01-01

Similar Documents

Publication Publication Date Title
EA200400664A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING METHFORMIN AND GLIBENCLAMIDE, APPLIED TO THE TREATMENT OF TYPE II DIABETES
RU95106821A (en) Cyclopeptides, method of their synthesis, pharmaceutical composition and method of its preparing
RU2005133665A (en) APPLICATION OF 10-HYDROXY-10,11-DIHYDROCARBAMAZEPINE DERIVATIVES FOR THE TREATMENT OF AFFECTIVE DISORDERS
JP2005511619A5 (en)
RU99121654A (en) MEANS FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH EXTREME PROLIFERATION OF EPITHELIAL PIGMENTAL RETAIN CELLS
RU2005132163A (en) 2- (BUTYL-1-SULFONILAMINO) -N- [1 (R) - (6-METHOXYpyridin-3-IL) -PROPYL] BENZAMIDE, ITS APPLICATION AS A MEDICINAL PRODUCT, AND ALSO CONTAINING HIS PHARES
RU2007119067A (en) MEANS FOR TREATMENT OF AN IRRITATED INTESTINAL SYNDROME WITH PREVENTION OF DIARRHEA
JP2004526760A5 (en)
RU2005135647A (en) COMBINATIONS INCLUDING PAROXETIN AND {1- (R) - (3.5-BIS-TRIFTOR-2-METHYLPHENYL) Ethylmethylamide} -2- (S) - (4-FLUOR-2-METHYLPHENYL) PIPERAZINE-1-CARBETONE DEPRESSIONS AND / OR ALARMS
JP2006520343A5 (en)
CA2457982A1 (en) Use of nefiracetam for treating neurodegeneration
RU2007125976A (en) METHOD FOR REDUCING, STABILIZING AND PREVENTING RIP PLAIN RICH LIPIDS
RU98101105A (en) NEW APPLICATION FOR MEDICAL PURPOSES
EA200400348A1 (en) CYPLATINE COMPOSITIONS OF REDUCED TOXICITY AND METHODS OF THEIR APPLICATION
RU97104062A (en) APPLICATION OF SELEGYLIN FOR TREATMENT OF EPILEPTIC DISEASES
RU2000125000A (en) COMPOSITION FOR ANTISEPTIC TREATMENT OF HAND SKIN AND OPERATION FIELD
RU2021136579A (en) NEW HEPATOPROTECTOR MEDICINES
TH41853A (en) Use of GLP-1 or a similar agent in the treatment of one area of myocardial infarction.
TH55743B (en) New morpholinobenzamade salt
RU2002106483A (en) A new class of physiologically active glycoproteins
RU99108789A (en) INHIBITOR OF SUBEPITELIAL POGGENITS
RU2002106185A (en) Salts of 4-amino-3-phenylbutanoic acid and a drug with anti-ischemic, antihypertensive, antiarrhythmic, nootropic and antihypoxic antivicity
RU2002129102A (en) TREATMENT OF SEPARATE DOSES OF AGENTS WITH VASCULAR DESTRUCTIVE ACTIVITY
TH84974A (en) Liquid pharmaceutical formulation containing compounds 3,7-diazabycloids [3,3,1] Nonane and methods of treatment associated with arrhythmia.
RU2003106339A (en) DRUG FOR TREATMENT OF ENDOMETRITIS IN COWS AND PIGS

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110306